Page last updated: 2024-12-06

taltrimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID71248
CHEMBL ID2107479
SCHEMBL ID347001
MeSH IDM0135727

Synonyms (25)

Synonym
taltrimide
2-(1,3-dioxoisoindol-2-yl)-n-propan-2-ylethanesulfonamide
81428-04-8
n-isopropyl-1,3-dioxo-2-isoindolineethanesulfonamide
unii-nq74u9qr5d
2h-isoindole-2-ethanesulfonamide, 1,3-dihydro-n-(1-methylethyl)-1,3-dioxo-
taltrimida [spanish]
taltrimidum [latin]
taltrimida
nq74u9qr5d ,
taltrimide [inn]
taltrimidum
CHEMBL2107479
SCHEMBL347001
AKOS016487334
NZKNHIQZWSVJGP-UHFFFAOYSA-N
2-(1,3-dioxoisoindolin-2-yl)-n-isopropyl-ethanesulfonamide
2-(1,3-dioxoisoindolin-2-yl)-n-isopropylethanesulfonamide
F2834-0106
my 117
Q27284993
2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-n-(propan-2-yl)ethane-1-sulfonamide
DTXSID50868612
2-(1,3-dioxoisoindolin-2-yl)-n-isopropylethane-1-sulfonamide
2-(1,3-dioxoisoindol-2-yl)-n-isopropylethanesulfonamide

Research Excerpts

Overview

Taltrimide is a lipophilic taurine derivative with definitive anticonvulsive effects in experimental epilepsy models.

ExcerptReferenceRelevance
"Taltrimide is a lipophilic taurine derivative with definitive anticonvulsive effects in experimental epilepsy models. "( Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients.
Keränen, T; Koivisto, K; Neuvonen, PJ; Partanen, VS; Riekkinen, PJ; Tokola, O,
)
1.96

Treatment

ExcerptReferenceRelevance
"Pretreatment with taltrimide, a lipophilic taurine derivative (intraperitoneal injection of 200 mg/kg for four days), led to similar results."( Taurine and osmoregulation. II. Administration of taurine analogues affords cerebral osmoprotection during chronic hypernatremic dehydration.
Del Pizzo, R; Finberg, L; Huxtable, RJ; Sturman, JA; Trachtman, H, 1988
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (71.43)18.7374
1990's2 (28.57)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]